Yao Liu1, Wei Yan2, Samer Tohme3, Man Chen3, Yu Fu4, Dean Tian4, Michael Lotze3, Daolin Tang3, Allan Tsung5. 1. Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; Department of Gastroenterology, The First Affiliated Hospital of Gannan Medical College, China. 2. Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States; Department of Gastroenterology, Huazhong University of Science and Technology, China. 3. Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States. 4. Department of Gastroenterology, Huazhong University of Science and Technology, China. 5. Department of Surgery, University of Pittsburgh Cancer Institute, Pittsburgh, PA, United States. Electronic address: Tsunga@upmc.edu.
Abstract
BACKGROUND & AIMS: The mechanisms of hypoxia-induced tumor growth remain unclear. Hypoxia induces intracellular translocation and release of a variety of damage associated molecular patterns (DAMPs) such as nuclear HMGB1 and mitochondrial DNA (mtDNA). In inflammation, Toll-like receptor (TLR)-9 activation by DNA-containing immune complexes has been shown to be mediated by HMGB1. We thus hypothesize that HMGB1 binds mtDNA in the cytoplasm of hypoxic tumor cells and promotes tumor growth through activating TLR9 signaling pathways. METHODS: C57BL6 mice were injected with Hepa1-6 cancer cells. TLR9 and HMGB1 were inhibited using shRNA or direct antagonists. HuH7 and Hepa1-6 cancer cells were investigated in vitro to determine how the interaction of HMGB1 and mtDNA activates TLR9 signaling pathways. RESULTS: During hypoxia, HMGB1 translocates from the nucleus to the cytosol and binds to mtDNA released from damaged mitochondria. This complex subsequently activates TLR9 signaling pathways to promote tumor cell proliferation. Loss of HMGB1 or mtDNA leads to a defect in TLR9 signaling pathways in response to hypoxia, resulting in decreased tumor cell proliferation. Also, the addition of HMGB1 and mtDNA leads to the activation of TLR9 and subsequent tumor cell proliferation. Moreover, TLR9 is overexpressed in both hypoxic tumor cells in vitro and in human hepatocellular cancer (HCC) specimens; and, injection in mice to knockdown either HMGB1 or TLR9 from HCC cells suppressed tumor growth in vivo. CONCLUSIONS: Our data reveals a novel mechanism by which the interactions of HMGB1 and mtDNA activate TLR9 signaling during hypoxia to induce tumor growth.
BACKGROUND & AIMS: The mechanisms of hypoxia-induced tumor growth remain unclear. Hypoxia induces intracellular translocation and release of a variety of damage associated molecular patterns (DAMPs) such as nuclear HMGB1 and mitochondrial DNA (mtDNA). In inflammation, Toll-like receptor (TLR)-9 activation by DNA-containing immune complexes has been shown to be mediated by HMGB1. We thus hypothesize that HMGB1 binds mtDNA in the cytoplasm of hypoxic tumor cells and promotes tumor growth through activating TLR9 signaling pathways. METHODS: C57BL6 mice were injected with Hepa1-6 cancer cells. TLR9 and HMGB1 were inhibited using shRNA or direct antagonists. HuH7 and Hepa1-6 cancer cells were investigated in vitro to determine how the interaction of HMGB1 and mtDNA activates TLR9 signaling pathways. RESULTS: During hypoxia, HMGB1 translocates from the nucleus to the cytosol and binds to mtDNA released from damaged mitochondria. This complex subsequently activates TLR9 signaling pathways to promote tumor cell proliferation. Loss of HMGB1 or mtDNA leads to a defect in TLR9 signaling pathways in response to hypoxia, resulting in decreased tumor cell proliferation. Also, the addition of HMGB1 and mtDNA leads to the activation of TLR9 and subsequent tumor cell proliferation. Moreover, TLR9 is overexpressed in both hypoxic tumor cells in vitro and in humanhepatocellular cancer (HCC) specimens; and, injection in mice to knockdown either HMGB1 or TLR9 from HCC cells suppressed tumor growth in vivo. CONCLUSIONS: Our data reveals a novel mechanism by which the interactions of HMGB1 and mtDNA activate TLR9 signaling during hypoxia to induce tumor growth.
Authors: Jane Tian; Ana Maria Avalos; Su-Yau Mao; Bo Chen; Kannaki Senthil; Herren Wu; Peggy Parroche; Stacey Drabic; Douglas Golenbock; Cherilyn Sirois; Jing Hua; Ling Ling An; Laurent Audoly; Greg La Rosa; Angelika Bierhaus; Peter Naworth; Ann Marshak-Rothstein; Mary K Crow; Katherine A Fitzgerald; Eicke Latz; Peter A Kiener; Anthony J Coyle Journal: Nat Immunol Date: 2007-04-08 Impact factor: 25.606
Authors: Michal Caspi Tal; Miwa Sasai; Heung Kyu Lee; Brian Yordy; Gerald S Shadel; Akiko Iwasaki Journal: Proc Natl Acad Sci U S A Date: 2009-02-05 Impact factor: 11.205
Authors: Samer Tohme; Hamza O Yazdani; Ahmed B Al-Khafaji; Alexis P Chidi; Patricia Loughran; Kerri Mowen; Yanming Wang; Richard L Simmons; Hai Huang; Allan Tsung Journal: Cancer Res Date: 2016-01-12 Impact factor: 12.701
Authors: Samer Tohme; Hamza O Yazdani; Yao Liu; Patricia Loughran; Dirk J van der Windt; Hai Huang; Richard L Simmons; Sruti Shiva; Sheng Tai; Allan Tsung Journal: Hepatology Date: 2017-05-22 Impact factor: 17.425
Authors: Lucia Cottone; Annalisa Capobianco; Chiara Gualteroni; Antonella Monno; Isabella Raccagni; Silvia Valtorta; Tamara Canu; Tiziano Di Tomaso; Angelo Lombardo; Antonio Esposito; Rosa Maria Moresco; Alessandro Del Maschio; Luigi Naldini; Patrizia Rovere-Querini; Marco E Bianchi; Angelo A Manfredi Journal: Oncoimmunology Date: 2016-01-08 Impact factor: 8.110
Authors: Madathilparambil V Suresh; Bivin Thomas; Vladislav A Dolgachev; Matthew A Sherman; Rebecca Goldberg; Mark Johnson; Aulina Chowdhury; David Machado-Aranda; Krishnan Raghavendran Journal: Shock Date: 2016-10 Impact factor: 3.454
Authors: Heejae Lee; Hee Jin Lee; In Hye Song; Won Seon Bang; Sun-Hee Heo; Gyungyub Gong; In Ah Park Journal: In Vivo Date: 2018 Nov-Dec Impact factor: 2.155